ABBV vs MRK
By Alex · Tickerpine
AbbVie Inc. vs Merck & Co., Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | MRK |
|---|---|---|
| Price | $295.03 | $147.76 |
| Market cap | $521.50B | $364.26B |
| P/E ratio | 50.7 | 149.3 |
| ROE | — | 5.06% |
| Profit margin | 15.67% | 3.64% |
| Revenue growth | 10.30% | 4.70% |
| Dividend yield | 2.35% | 2.30% |
| Beta | 0.19 | 0.12 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs MRK in plain English
- ABBV is the bigger company — about 1.4× the market cap of MRK.
- ABBV is cheaper on earnings (P/E 50.7 vs 149.3).
- ABBV is growing revenue faster (10% vs 5%).
- ABBV has the higher dividend yield (2.35% vs 2.30%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.